Ausam Battles Keryx Over Share Losses

Law360, New York (August 3, 2006, 12:00 AM EDT) -- Biopharmaceutical company Ausam Biotechnologies Inc. went head to head with Keryx Biopharmaceuticals Inc. in a federal bankruptcy court this week in a bid to force Keryx to shell out more than half a million dollars for shares it says it never received.

Ausam, which filed for Chapter 11 protection in early February, has ceased operations but continues to market its anti-viral program, one of the company’s two product lines. The anti-viral program has yet to be sold, but Ausam has said it has plans to do...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.